Cellectar reports Phase 2b subgroup data for iopofosine I 131 in WM

October 15, 2026 7:01 AM

Cellectar Biosciences (NASDAQ: CLRB) presented subgroup analysis data from its Phase 2b CLOVER WaM clinical trial at the International Workshop ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found